Pharmacologically directed ara-C therapy for refractory leukemia

Seminars in Oncology

Volumn 12, Issue 2 SUPPL. 3, 1985, Pages 20-30

  Plunkett, William ^a,b   Iacoboni, Stephen ^a,b   Estey, Elihu ^a,b   Danhauser, Lynn ^a,b   Liliemark, Jan O ^a,b   Keating, Michael J ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; CYTARABINE TRIPHOSPHATE;

BLOOD AND HEMOPOIETIC SYSTEM; CANCER CHEMOTHERAPY; CELL METABOLISM; CLINICAL ARTICLE; DNA SYNTHESIS; DRUG DOSE; DRUG THERAPY; DRUG TISSUE LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; PHARMACOKINETICS; PHARMACOLOGY; THERAPY;

ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; ARABINONUCLEOTIDES; CYTARABINE; DNA; DRUG RESISTANCE; HUMANS; KINETICS; LEUKEMIA;

EID: 0021847172     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cytosine arabinoside transport by human leukemic cells
2. Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro
3. Deoxycytidine kinase: Properties of the enzyme from human leukemia granulocytes
4. Metabolism of 1-β-D-arabinofuranosylcytosine in human leukemic cells
5. Correlation between leukemic cell retention of 1-β-D-arabinofurarosylcytosine 5′-triphosphate and response to therapy
6. Factors determining cell sensitivity to methotrexate: Studies of folate and deoxyribonucleoside triphosphate pools in five mammalian cell lines
7. Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-β-D-arabinofurarosylcytosine and the 5′-triphosphate of 9-β-D-arabinofurarosyladenine
8. Kinetics of inhibition of deoxynibonucleotide-polymenizing enzyme activities from normal and leukemic human cells by 9-β-D-arabinofurarosyladenine 5′triphosphate and 1-β-D-arabinofuranosylcytosine 5′-triphosphate
9. Studies in mouse L-cells on the incorporation of 1-β-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-β-D-arabinofuranosylcytosine 5′-triphosphate
10. Correlation of cytotoxicity with incorporation of ara-C into DNA
11. Distribution of kinase and deaminase of 1-β-D-arabinofuranosylcytosine in tissues of man and mouse
12. Cytidine deaminase and the development of resistance to arabinosylcytosine
13. Prognostic potential of araCTP pharmacodynamics during therapy of acute leukemia with high-dose araC
14. Pharmacologically-directed schedules of high dose ara-C (hd-araC) for velapsed acute leukemia (RAL)
15. Clinical results of pharmacologically-directed schedules of highdose araC for relapsed acute leukemia (RAL)
16. Pharmacologic direction of continuous infusion high dose araC (CIHDAC) for refractory acute leukemia (RAL) and chronic myelogenous leukemia blast crisis (CML-BC)
17. Quantitation of 1-β-D-arabinofurarosylcytosine 5′triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofurarosylcytosine therapy
18. Simultaneous determination of 1-β-D-arabinofurarosylcytosine 5′-triphosphate and 3-deazaurdine 5′-triphosphate in human leukemia cells by high-performance liquid chromatography
19. A radioimmunoassay for cytosine arabinoside
20. Failure of remission induction in acute myelocytic leukemia